Murphy & Mullick Capital Management Corp Takes Position in Eli Lilly and Company (NYSE:LLY)

Murphy & Mullick Capital Management Corp acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,637 shares of the company’s stock, valued at approximately $1,264,000. Eli Lilly and Company accounts for about 1.2% of Murphy & Mullick Capital Management Corp’s investment portfolio, making the stock its 19th largest holding.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Florida Financial Advisors LLC increased its stake in Eli Lilly and Company by 76.4% in the fourth quarter. Florida Financial Advisors LLC now owns 1,337 shares of the company’s stock valued at $1,032,000 after purchasing an additional 579 shares in the last quarter. Aire Advisors LLC grew its holdings in shares of Eli Lilly and Company by 6.7% in the 4th quarter. Aire Advisors LLC now owns 2,110 shares of the company’s stock valued at $1,629,000 after buying an additional 132 shares during the period. Baxter Bros Inc. grew its holdings in shares of Eli Lilly and Company by 9.0% in the 4th quarter. Baxter Bros Inc. now owns 2,157 shares of the company’s stock valued at $1,665,000 after buying an additional 179 shares during the period. Keystone Investors PTE Ltd. raised its stake in Eli Lilly and Company by 1,657.0% during the 4th quarter. Keystone Investors PTE Ltd. now owns 13,933 shares of the company’s stock worth $10,756,000 after buying an additional 13,140 shares during the period. Finally, Bay Capital Advisors LLC bought a new position in Eli Lilly and Company during the fourth quarter worth about $1,179,000. Institutional investors own 82.53% of the company’s stock.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $852.35 on Wednesday. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The stock has a market capitalization of $808.17 billion, a price-to-earnings ratio of 72.79, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a twelve month low of $711.40 and a twelve month high of $972.53. The company has a 50-day simple moving average of $839.56 and a two-hundred day simple moving average of $837.61.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company announced that its Board of Directors has authorized a share buyback program on Monday, December 9th that permits the company to buyback $15.00 billion in shares. This buyback authorization permits the company to reacquire up to 2% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s management believes its stock is undervalued.

Analyst Ratings Changes

Several equities research analysts have issued reports on LLY shares. Citigroup lowered their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Bank of America reissued a “buy” rating and set a $997.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Truist Financial boosted their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Finally, Morgan Stanley set a $1,146.00 target price on Eli Lilly and Company in a report on Thursday, March 6th. Three analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,009.72.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.